Bristol-Myers Squibb Archives

News and Trends 22 Dec 2016

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the promising CAR-T therapies. PsiOxus Therapeutics, based in Oxford, develops immuno-oncolytic viruses to treat solid tumors. Its technology attracted a partnership with Bristol-Myers Squibb earlier this year, which is now offering the British biotech an impressive €850M […]

December 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology. Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Nov 2016

Results from 45% of Clinical Trials are kept Secret

A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […]

November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Oct 2016

It’s not over yet for Opdivo; AbbVie takes a stand in Leukemia

The Committee on Medicinal Products for Human Use (CHMP) has handed down a pair of positive opinions of Opdivo and AbbVie’s leukemia therapy in their quests for EMA approval. Before the European Commission reviews an application for market authorization, it crosses the collective desk of the Committee on Medicinal Products for Human Use (CHMP). If […]

October 17, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 10 Oct 2016

Big Pharmas Battle to be the Lung Cancer Leader at ESMO

Merck, Roche and BMS have unveiled updated results in Copenhagen as the companies duke it out for the leadership in lung cancer therapies. The conference of the European Society of Medical Oncology (ESMO) is underway in Copenhagen, and big pharma’s efforts to cure lung cancer are stealing the show. Three titans, Roche (Genentech), Merck and […]

October 10, 2016 - 3 minutesmins - By Evelyn Warner

cormorant interleukin 8 bms immuno oncology

News and Trends 7 Jul 2016

BMS to acquire Swedish Immuno-Oncology Biotech for €460M

Bristol-Myers Squibb wants to strengthen its immuno-oncology even further. For this, it is acquiring Cormorant – a Biotech developing immunotherapies in a deal that could go up to €460M. Based at the Karolinska Institute Science Park in Stockholm (Sweden), Cormorant was a private Biotech focusing on cancer immunotherapies. Its main program was HuMax-IL8, which is currently in Phase […]

July 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

bristol myers squibb immunooncology cancer opdivo psioxus

News and Trends 1 Jul 2016

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Oxfordshire based PsiOxus will team up with the Immuno-Oncology Giant, Bristol-Myers Squibb, to test the combinatorial effect of their blockbuster drug with an Oncolytic viral therapy in late-stage cancer patients. Together they will evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ Enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Opdivo blockbuster (nivolumab), which […]

July 1, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Jun 2016

New Massive €250M Investment Fund Closed for European Biotech

Life Sciences Partners (LSP) has closed its new life sciences fund, ‘LSP5’. The fund surpassed its €152M target and reached the ‘hard cap’ of €250M, making it one of the largest life sciences funds in the EU. LSP is one of the oldest and most successful Biotech investors in Europe. It claims over 25% return […]

June 7, 2016 - 2 minutesmins - By Dani Bancroft

innate pharma immunooncology biotech cancer orega sanofi

News and Trends 11 Jan 2016

A French Biotech is Monopolising Immuno-Oncology with Big Euro Deals

Marseille’s Innate Pharma is building an Immuno-Oncology Monopoly, deal by deal. Selling to the French Pharma Giant, Sanofi, this 112 employee biotech has used their Sanofi-income to buy up Lyon-based Orega Biotech‘s checkpoint inhibitor program. Sanofi and Innate Pharma will work together on the generation and evaluation of up to two bispecific NK cell engagers, […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 24 Nov 2015

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU. Bristol-Myers Squibb (BMS) has partnered with Life Sciences Partners in Munich to highlight novel immuno-oncology technologies which could be the next blockbusters in the field. Together the two have conspired a […]

November 24, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Innate Pharma receives $5M from its Monster-deal with BMS

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011. This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

future biomarkers immuno oncology lymphocytes

News and Trends 31 Aug 2015

Review: The Future of Biomarkers in Immuno-Oncology

Immuno-oncology is a Biotech field that is more than just hype – it could solve one of humanity’s biggest health challenges: Cancer. In order to bring more effective treatments with fewer side-effects, Biomarkers will play a key role. I wanted to get an expert view on the subject, so I called Bernhard Sixt, CEO of the […]

August 31, 2015 - 5 minutesmins - By Philip Hemme

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Bristol-Myers Squibb

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

Results from 45% of Clinical Trials are kept Secret

It’s not over yet for Opdivo; AbbVie takes a stand in Leukemia

Big Pharmas Battle to be the Lung Cancer Leader at ESMO

BMS to acquire Swedish Immuno-Oncology Biotech for €460M

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

New Massive €250M Investment Fund Closed for European Biotech

A French Biotech is Monopolising Immuno-Oncology with Big Euro Deals

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

Innate Pharma receives $5M from its Monster-deal with BMS

Review: The Future of Biomarkers in Immuno-Oncology

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!